Could the Hurricane Energy share price be the bargain of the year?

G A Chester weighs up the potential of exciting oil stock Hurricane Energy plc (LON:HUR) and a pharma firm aiming to rise like a phoenix.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There’s no shortage of loss-making-but-high-potential companies on the stock market. Oil explorers and developers and pharmaceuticals and medical technology firms offer the prospect of particularly big gains for investors who identify the right company at the right price.

Of course, this is easier said than done. For every millionaire-maker there are dozens of duds. Today, I’m weighing up the potential of oil stock Hurricane Energy (LSE: HUR) and pharma player Circassia (LSE: CIR), which released its annual results today.

Collapse

Heavily backed by cornerstone investors Neil Woodford and his protégé at former employer Invesco, Circassia pursued the development of a whole platform of allergy treatments that were said to build immunity quicker than existing remedies and without the risk of anaphylactic shocks. When its lead cat allergy failed a Phase III study, the entire programme collapsed.

At the height of investor confidence, Circassia was a member of the FTSE 250 index, with a share price of 350p and market capitalisation of over £1bn. Today, it’s on the AIM market, its share price is 31.5p (down a little on the back of its results) and its market cap is £118m. Its accounts show an accumulated loss of over half-a-billion quid.

However, it now has a small portfolio of revenue-generating products, including via a commercial collaboration with AstraZeneca, which has also become a 19% shareholder in Circassia. Could the stock be set to rise like a phoenix?

Recovery?

Just over a year ago, I wrote that I wouldn’t touch Circassia with a bargepole, noting also a 5.42% short position in the stock held by hedge fund Mangrove.

Today’s results showed a £37.2m operating loss on revenue of £48.3m. There are signs of promising revenue growth, and with the share price much lower than a year ago, the valuation picture has improved.

However, continued losses are forecast into next decade and Mangrove has maintained its chunky short position. I’m not convinced the risk/reward proposition with Circassia is compelling, and so continue to see it as a stock to avoid at this stage.

Share price to double?

By contrast, when I last wrote about Hurricane Energy (November 2017), I felt its progress to date, potential to become a major player in the West of Shetland region, and share price of 26.75p (market cap £524m) represented an attractive risk/reward proposition. The shares are currently trading at around 47p (market cap £921m), but I continue to see a compelling investment opportunity.

The company is on track to deliver first oil from its 100%-owned Lancaster discovery before the end of June. Planned initial production is 17,000 barrels a day, and management expects to generate over $200m in operating cash flow on a full-year run-rate basis at a $60 a barrel Brent oil price.

Meanwhile, a 50% farm-in to its Warwick and Lincoln fields by Spirit Energy, providing up to $387m, has enabled an acceleration of activity, including the drilling of three wells this year, one of which was spudded last month.

If we see the company successfully executing on this year’s work programme, I think the share price could easily double from its current level. And with total 2P reserves and 2C contingent resources across the asset base standing at 2.3bn barrels net to Hurricane, there’s potential for the value of the company to continue increasing as time goes on.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Group of young friends toasting each other with beers in a pub
Investing Articles

FTSE 100 shares: has a once-a-decade chance to build wealth ended?

The FTSE 100 index has had a strong 2025. But that doesn't mean there might not still be some bargain…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

I asked ChatGPT for its top passive income ideas for 2026 and it said…

Stephen Wright is looking for passive income ideas for 2026. But can asking artificial intelligence for insights offer anything valuable?

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Here’s how a 10-share SIPP could combine both growth and income opportunities!

Juggling the prospects of growth and dividend income within one SIPP can take some effort. Our writer shares his thoughts…

Read more »

Tabletop model of a bear sat on desk in front of monitors showing stock charts
Investing Articles

The stock market might crash in 2026. Here’s why I’m not worried

When Michael Burry forecasts a crash, the stock market takes notice. But do long-term investors actually need to worry about…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Is this FTSE 250 retailer set for a dramatic recovery in 2026?

FTSE 250 retailer WH Smith is moving on from the accounting issues that have weighed on it in 2025. But…

Read more »

Young Black woman using a debit card at an ATM to withdraw money
Investing Articles

I’m racing to buy dirt cheap income stocks before it’s too late

Income stocks are set to have a terrific year in 2026 with multiple tailwinds supporting dividend growth. Here's what Zaven…

Read more »

ISA Individual Savings Account
Investing Articles

Aiming for a £1k passive income? Here’s how much you’d need in an ISA

Mark Hartley does the maths to calculate how much an investor would need in an ISA when aiming for a…

Read more »

Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.
Investing Articles

Is investing £5,000 enough to earn a £1,000 second income?

Want to start earning a second income in the stock market? Zaven Boyrazian breaks down how investors can aim to…

Read more »